|
|
|
|
|
|
|
Dear Sir or Madam,
in our first newsletter, we would like to inform you about the current status of the Collaborative Biobank.
|
|
|
|
|
|
|
|
  Since our official launch on 01.06.2017 we have accomplished numerous projects and are now in collaboration with ten clinics throughout Germany.
Thanks to their enthusiastic work, we have been able to store 28,636 blood samples in the biobank to date (May 2019), including 2,710 patient and 25,926 donor samples. Our sample manager, the DKMS Life Science Lab, receives an average of 16 to 20 samples daily for storage in the biobank.
In addition to our efforts to attract more national centres to participate in the Collaborative Biobank, we took the first steps towards internationalisation this year. We presented the Collaborative Biobank project at a meeting of the Dutch and Belgian collection centres and are currently exploring the possibilities of cooperation.
With this newsletter we would also like to refer you to our website, where you will find general information about the Collaborative Biobank as well as news and updates on our research projects.
|
|
|
|
|
|
|
|
|
|
With the resources of the Collaborative Biobank (CoBi), several research projects have been supported and realised.
In a joint research project involving hospitals across Europe and the US, specific receptors on natural killer cells (NK cells) were investigated, so-called killer cell immunoglobulin-like receptors (KIR) and their binding partners (ligands). The results of the research project were presented in December 2018 at the Congress of the American Society of Hematology (ASH). The poster (Classification of Donor KIR-Genotype Information to Predict Outcome after Unrelated Hematopoietic Stem Cell Transplantation: The Jury Is Still Out) was lively visited of leading researchers. The presented data underlines the relevance of KIR and NK cells in the context of stem cell transplantation. During the ASH Congress, the results presented were again discussed with Kathy Hsu, an expert on the field of KIR receptors, and other leading KIR researchers in the context of leukemia. Further cooperation projects were agreed on.
For more information on our research projects, which have been carried out using the Collaborative Biobank, please visit our Collaborative Biobank website.
|
|
|
|
|
|
 The hypothesis, that KIR2DS1-positive donors with favorable combinations of KIR3DL1 alleles and their ligands faciliate a better control of leukemia in patients with acute myeloid leukemia (AML), was analysed in another retrospective study of patients with myelodysplastic syndrome (MDS). Existing samples from the Collaborative Biobank and medical data requested from the EBMT Registry and the CIBMTR were used.
This research work, entitled "Does Donor KIR-Genotype 9 impact outcome after unrelated hematopoietic stem cell transplantation for myelodysplastic syndromes or secondary acute myeloid leukemia?", was presented at the spring meeting of the European Society for Blood and Marrow Transplantation (EBMT) and was awarded the prize for best poster from 800 exhibited papers!
|
|
|
|
|
|
|
|
|
|
|
The DKMS is a e-mail sender certified by the CSA.
|
|
|
|
You receive this newsletter because you are contract- or collaboration partner of CoBi. The dispatch takes place according to our
privacy policy. If you no longer wish to receive the newsletter, you can unsubscribe at any time by clicking
here. Also you can communicate this to us by E-Mail to
nonews@dkms.de or to the contact data indicated in the imprint.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Imprint
|
|
|
|
|
|
DKMS gemeinnützige GmbH
Kressbach 1
72072 Tübingen
Deutschland
T 0 70 71 9 43-0
F 0 70 71 9 43-1499
dkms.de
news@dkms.de
Executive board: Sirko Geist, Dr. Elke Neujahr, Dr. Dr. Alexander Schmidt
Commercial Register No.:
Commercial Register, Department B of Stuttgart District Court HRB 381293
|
|
|
|
|
|
|
